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Introduction
The DOLAB study is a parallel group, fixed dose, randomised,
double blind, placebo controlled trial of DHA supplementation
(600 mg/day for 16 weeks) in n = 362 healthy children aged
7-9 years from mainstream schools (n = 74) in Oxfordshire,
UK. (Clinical Trials.gov NCT01066182).
Research Question:
• Can supplementation with Omega-3 (DHA) improve read-
ing, working memory and behaviour in underperforming but
otherwise healthy children?
Methods
Eligibility Criteria:
• Children aged 7–9 years with English as a first language, no
major physical or mental health problems.
•No omega-3 supplement use in previous 6 months, nor eating
fish >2× a week.
•Reading performance ≤33rd centile as confirmed at initial
screening. NB: Owing to anticipated problems there was
a protocol amendment and recruitment was widened
from the ≤20thcentile before the first child was ran-
domised.
Children invited to participate:
n=1376
Consented to take part in
cross sectional study
n = 675
Did not consent
n =701
Randomized to take part in RCT
n = 362
Did not meet inclusion criteria
n=313
Baseline
Active supplement n=180
Baseline
Placebo n=182
Post-Intervention
Active-Supplement n=179
Lost at Post-Intervention n=1
Post-Intervention
Placebo n=180
Lost at Post-Intervention n=2
Study assessments:
These assessments were carried out on all children at the initial
screening and repeated at the 16 week follow-up.
•Reading performance - (British Ability Scales single word
reading)
•Working memory - (British Ability Scales Recall of Digits
Forward and Backward)
• Behaviour Parent Ratings (Conner’s Parent Rating Scales
Long Version (CPRS-L)
• Behaviour Teacher Ratings (Conner’s Teacher Rating
Scales Long Version (CTRS-L)
DHA Omega-3 Supplementation
and Reading Improvement
Change in Age-standardized Reading Scores
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Reading − Change Scores by Treatment Group
ITT analyses showed no effect of DHA on reading in the full sample, but
significant effects in the pre-planned subgroup of 224 children whose initial
reading performance was ≤20th centile (the target population in our original
study design), and these were even more pronounced in those ≤10th centile.
Reading Age at baseline, and change scores
Months (Sd.)
Baseline Change scores
Active Placebo Active Placebo
All randomized 86.1 (10.0) 87.1 (9.7) 4.7 (4.7) 4.8 (4.6)
(n=362)
Reading ≤ 20th centile 82.5 (9.1) 84.1 (8.6) 4.9 (4.7) 4.1 (4.0)
(n=224)
Reading ≤ 10th centile 77.3 (7.3) 80.8 (7.9) 5.7 (4.8) 3.8 (4.1)
(n=105)
In children with initial reading ≤20th centile, DHA led to an additional
0.8 months reading age gain compared with placebo, while in those
initially reading ≤10th centile, the additional reading age gain from
treatment was 1.9 months.
Reading ages would typically increase by 4 months over a 16-week pe-
riod, so the gains from DHA supplementation in these poorer readers were
around 20% and 50% greater, respectively, than would normally be ex-
pected, helping these children to catch up with their peer group.
DHA Omega-3 Supplementation and Behaviour
ADHD (Conner’s Parent Rating Scales)
p=.01 p=.06 p=.02 p=.07 p=.68 p=.16 p=.17
0
−
1
−
2
−
3
−
4
−
5
−
6
−
7
M
ea
n 
Ch
an
ge
 S
co
re
Pr
e−
/P
os
t−
In
te
rv
en
tio
n 
(M
ea
n ±
1 S
E)
Opp
ositio
nal
Cog
nitive
 Pro
blem
s
Hyp
erac
tivity Anxi
ety
Perf
ectio
nism
Soci
al Pr
oble
ms
Psyc
hoso
mati
c
Active Placebo
Whole Sample (n=362)
Change Scores for CPRS−L (Sub−Scales)
DHA Omega-3 supplementation
reduced ratings on the Sub-Scales for:
•Oppositional (p=.01)
•Hyperactivity (p=.02)
Teacher reported outcomes (CTRS-L) indicated
differences on perfectionism (p<0.03) but not on
other outcomes.
p=.04 p<.01 p<.01 p<.01 p=.09 p=.02 p=.03
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Change Scores for CPRS−L (Global−Scales)
DHA Omega-3 supplementation
reduced ratings on the Global-Scales for:
•ADHD Index (p=.04)
•Restless Impulsive (p<.01)
• Emotional Liability (p<.01)
•Global Total (p<.01)
•DSM-IV Hyperactive (p=.02)
•DSM-IV Total ADHD (p=.03)
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DHA Omega-3
Supplementation and
Working Memory
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Working Memory − Change Scores by Treatment Group
There were no significant group differences on the primary out-
come of change scores, although post-intervention scores on Re-
call of Digits Forward were higher in the active treatment group
as a whole (Active Mean=42.6, Sd=8.4; Placebo Mean=41.2,
Sd=7.7, p<0.04). There was also a suggestion that the slight
group difference in favour of active treatment increased with the
degree of reading impairment, as illustrated.
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Conclusions
•The effects of DHA on children’s reading progress
were found to vary with initial reading perfor-
mance, with significant benefits found only for the
poorest readers.
•Parent-rated behavior problems (ADHD-type
symptoms) were significantly reduced by active
treatment, but little or no effects were seen for ei-
ther teacher-rated behaviour or working memory.
•DHA supplementation therefore appears to be a
safe and effective way to improve reading and be-
haviour in healthy but underperforming children
from mainstream schools.
• Since such children are known to be at risk of
poorer educational and occupational outcomes,
and in light of the promising findings from this
trial, we are currently under-taking a replication
study (DOLAB II), specifically targeting those
children whose baseline reading performance is
≤20thcentile.
